clinical trial · NCT06997029
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb·phase1·recruiting·n = 234
Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian CancerBMS-986500PalbociclibFulvestrant
brief summary
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
started
Aug 1, 2025
primary completion
Dec 14, 2028
completion
Dec 14, 2028
last updated
Jul 2, 2026
official title
A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol